Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas-Reference-Cited by-同舟云学术

Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas

Published:2015-11 Issue:11 Volume:21 Page:1914-1920
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Nieto Yago^ORCID,Valdez Benigno C.,Thall Peter F.,Ahmed Sairah,Jones Roy B.,Hosing Chitra,Popat Uday,Shpall Elizabeth J.,Qazilbash Muzaffar,Gulbis Alison,Anderlini Paolo,Alousi Amin,Shah Nina,Bashir Qaiser,Liu Yan,Oki Yasuhiro,Hagemeister Frederick,Fanale Michelle,Dabaja Bouthaina,Pinnix Chelsea,Champlin Richard,Andersson Borje S.

Funder

Otsuka Pharmaceutical Development and Commercialization Inc.

National Cancer Institutes

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference38 articles.

1. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial;Linch;Lancet,1993

2. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial;Schmitz;Lancet,2002

3. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma;Philip;N Engl J Med,1995

4. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era;Gisselbrecht;J Clin Oncol,2010

5. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group;Blay;Blood,1998

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Preparative Regimens Used in Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapies;Manual of Hematopoietic Cell Transplantation and Cellular Therapies;2024

2. Safety and efficacy of a new high‐dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high‐risk myeloma: Matched‐pair comparisons with concurrent control cohorts;American Journal of Hematology;2023-12-15

3. High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma;Transplantation and Cellular Therapy;2023-11

4. Relapsed/Refractory Primary Mediastinal B-cell Lymphoma: Where do we Stand?;Transplantation and Cellular Therapy;2023-11

5. Intravenous Busulfan, Dimethylacetamide and neurotoxicity after high-dose pretransplant conditioning chemotherapy;Bone Marrow Transplantation;2023-03-25